FRM
HRMY icon

Fox Run Management’s Harmony Biosciences HRMY Stock Holding History

Fox Run Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,738
Closed -$813K – 1041
2025
Q4 		$813K Buy
+21,738
New +$715K 0.13% 295
2025
Q2 		– Sell
-6,071
Closed -$201K – 1016
2025
Q1 		$201K Buy
+6,071
New +$218K 0.03% 797
2023
Q3 		– Sell
-6,847
Closed -$241K – 822
2023
Q2 		$241K Sell
6,847
-4,814
-41% -$166K 0.07% 520
2023
Q1 		$381K Buy
+11,661
New +$531K 0.12% 326

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Fox Run Management's HRMY Position: Q1 2026 in Review

Fox Run Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 21,738 shares — an estimated $813K sold.

Fox Run Management first reported a position in HRMY in Q1 2023 and held it in 4 quarters. The position peaked at $813K in Q4 2025. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Fox Run Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 21,738 Harmony Biosciences shares in Q1 2026, an estimated $813K.
  • Fox Run Management first reported a position in Harmony Biosciences in Q1 2023 and held it in 4 quarters.
  • Fox Run Management's Harmony Biosciences position peaked at $813K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.